Topics

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Metabolic Diseases Diabetes Chronic Inflammation Oxidative Stress

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly grouped under nonalcoholic fatty liver disease, identifies hepatic steatosis in a metabolic-risk context. Its increasing prevalence parallels overnutrition, physical inactivity, obesity, insulin resistance, and metabolic syndrome. MASLD can progress from steatosis to metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma, while also increasing type 2 diabetes, chronic kidney disease, cancer, and cardiovascular risk. Cardiac-related causes account for much of the mortality burden, so MASLD is now studied as a cardiovascular-liver-metabolic disorder rather than an isolated hepatic phenotype. The nomenclature shift has intensified work on mechanisms, risk classification, and treatment-response heterogeneity Its multisystem definition is clinically important because cardiovascular events can occur without parallel progression of fibrosis, and severe liver disease can develop in a lower-risk metabolic phenotype[1][2].

Hepatic lipid accumulation produces lipotoxicity that engages endoplasmic-reticulum stress, oxidative stress, organelle dysfunction, ferroptosis, and inflammatory injury. Unhealthy diet, dysfunctional adipose tissue, insulin resistance, and subclinical inflammation are shared upstream drivers of liver and cardiovascular disease. The steatotic, inflamed liver can then alter systemic physiology through excess glucose production, atherogenic dyslipidemia, procoagulant factors, hepatokines, and microRNAs, affecting endothelium, myocardium, and vasculature. Gut microbial dysbiosis may further modify lipid handling and inflammatory signaling. These reciprocal pathways help explain associations with atherogenesis, diastolic dysfunction, valvular calcification, arrhythmia, and epicardial fat, but the relative contribution of liver-specific injury versus common metabolic exposure varies among patients Hepatic inflammation also changes coagulation and vascular signaling, so mechanistic studies should quantify liver-derived mediators rather than attribute every association to shared obesity or diabetes[1][3][4].

Clinical application begins with dual risk assessment. Large population data associate MASLD and related steatotic liver disease with myocardial infarction, ischemic stroke, heart failure, and cardiovascular death. Noninvasive serum and imaging tests can identify hepatic disease, while cardiovascular screening should not depend solely on established atherosclerotic risk factors. Weight loss remains the most effective nonpharmacological intervention, but liver and cardiometabolic responses to treatment are not uniform. Data-driven clustering has identified a liver-specific phenotype with genetically linked, rapidly progressive liver disease and limited cardiovascular risk, and a cardiometabolic phenotype marked by dysglycemia, hypertriglyceridemia, and higher cardiovascular and diabetes risk. This distinction supports tailored surveillance and metabolism-based therapy instead of treating identical liver imaging as a uniform prognosis The cluster findings provide a practical hypothesis for precision care, but simple clinical variables must reproduce these groups prospectively before they guide treatment intensity[2][4][5][6].

Major gaps concern causality, phenotyping, and endpoint selection. Current data do not yet justify routine precision medicine, and improvement in steatosis, fibrosis markers, or body weight does not guarantee cardiovascular benefit. Resmetirom and incretin-based approaches primarily address metabolic liver injury, whereas hepatic inflammation remains a key driver of progression from steatosis to steatohepatitis and fibrosis. Future trials should stratify liver-specific and cardiometabolic phenotypes, measure hepatic and cardiovascular outcomes together, and define how genetics, adipose dysfunction, microbiota, immune state, fibrosis, and treatment exposure modify response. Multidisciplinary care must also determine when cardiologists should screen for MASLD and when hepatologists should intensify cardiovascular prevention. The field needs validated biomarkers that distinguish shared metabolic risk from liver-derived cardiovascular signaling and identify patients who require pathway-specific intervention Outcome studies should report liver failure, diabetes, kidney disease, cardiovascular events, cancer, and mortality together to avoid optimizing one organ while leaving another risk unchanged[1][5][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-12815A MCC950 sodium
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-12815 MCC950
MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-100381 Nigericin sodium salt
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.

Source: Streptomyces hygroscopicus

Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-127019 Nigericin
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-16578 GW9662
GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
PPAR  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
228
HY-17386 Rosiglitazone
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM), with blood-brain barrier permeability. Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
PPAR   TRP Channel   Autophagy   Ferroptosis   Apoptosis  
Digestive System Disease   Prostate Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Type 2 Diabetes   Obesity  
197
HY-112879 Mito-TEMPO
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
Calcium Channel   Apoptosis   Mitochondrial Metabolism   NOD-like Receptor (NLR)   PINK1/Parkin   Autophagy  
Ischemic Stroke   Osteoporosis   Chronic Kidney Disease  
186
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-14649 Retinoic acid
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
Organoid   RAR/RXR   PPAR   Endogenous Metabolite   Autophagy  
Cancer   Digestive System Disease   Depression   Digestive System Inflammation   Obesity  
150
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-15372 GW6471
GW6471 is a selective peroxisome proliferator-activated receptor α (PPARα) antagonist. GW6471 reduces cancer stem cell viability, proliferation, and spheroid formation. GW6471 induces apoptosis and causes metabolic impairment including energy imbalance. GW6471 can be used for the research of paragangliomas and triple-negative breast cancer.
PPAR   Apoptosis  
Triple-Negative Breast Cancer  
85
HY-L043 Lipid Compound Library
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 2,028 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Structure Classified Libraries

84
HY-L046 Anti-Cardiovascular Disease Compound Library
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Disease Focused Libraries

84
HY-L145 Antihypertensive Compound Library
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 930 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Disease Focused Libraries

83
HY-L241 Chinese Baijiu Compound Library
Chinese Baijiu is one of the oldest alcoholic beverages in the world, with a history of over 2,000 years. It can be classified into 12 aroma types based on its fragrance and flavor characteristics. The specific flavor profile of Baijiu is determined by the composition and concentration of certain compounds. These trace compounds, present in low concentrations yet rich in esters, alcohols, acids, lactones, aldehydes, ketones, acetals, alkenes, and others, significantly influence the flavor of Baijiu. Additionally, some active components in Baijiu possess antioxidant properties, and moderate consumption may help reduce the risk of cardiovascular diseases, dementia, and insulin resistance. Therefore, studying the chemical composition of Baijiu is crucial for promoting its fermentation process and enhancing its flavor and quality. MCE has compiled included 674 Chinese Baijiu components, which can be used for drug development, Baijiu fermentation, and research related to Baijiu flavor and aroma.

Compound Characteristic Classified Libraries

83
HY-L263 Energy Metabolites Library
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research. The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.

Signaling Pathway Targeting Libraries

83
HY-L923 Ion Channel Lead-like Compound Library
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields. MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Focused and target libraries

83
HY-16569 Colchicine
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
Environmental Pollutants   Microtubule/Tubulin   Autophagy   Apoptosis   NOD-like Receptor (NLR)  
Digestive System Disease   Lung Cancer   Prostate Cancer   Viral Infection   Coronavirus Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Alzheimer's Disease   Lung Fibrosis  
77
HY-13443 Exendin-4
Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease.
GLP Receptor   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Type 2 Diabetes  
72
HY-Y1269D Ammonium chloride, for molecular biology
Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases.
TGF-beta/Smad   Apoptosis   Chloride Channel  
Cancer   Epilepsy  
62
HY-14452A Fatostatin hydrobromide
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
57
HY-14452 Fatostatin
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
57
HY-13956 Pioglitazone
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research.
PPAR   Ferroptosis  
Prostate Cancer   Pancreatic Cancer   Viral Infection   Coronavirus Infection   Depression   Digestive System Inflammation   Glucose Metabolism   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Obesity  
53
HY-12364 C75
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. C75 is a potent CPT1A activator.
Carnitine Palmitoyltransferase (CPT)   Fatty Acid Synthase (FASN)  
Digestive System Disease   Breast Cancer   Prostate Cancer   Digestive System Inflammation   Obesity  
52
HY-114118C Semaglutide sodium
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-A0070 Liothyronine sodium
Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
46
HY-P0264 Exendin(9-39) amide
Exendin (9-39) amide (Avexitide) is a competitive GLP-1R antagonist. Exendin (9-39) amide blocks the Semaglutide (HY-114118)-induced increase in insulin secretion and also attenuates the hypoglycemic effect of Semaglutide. Exendin (9-39) amide abolishes the islet-protective effect of Liraglutide. Exendin (9-39) amide can be used in research on type 2 diabetes and type 1 diabetes.
GLP Receptor  
Type 1 Diabetes   Type 2 Diabetes  
46
HY-A0070A Liothyronine
Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR.
Thyroid Hormone Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease  
46
HY-P0014 Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease   Type 1 Diabetes   Psoriasis   Chronic Obstructive Pulmonary Disease   Type 2 Diabetes   Obesity  
43
HY-15027 5-Aminosalicylic Acid
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
PPAR   PAK   NF-κB   Endogenous Metabolite  
Digestive System Disease   Colitis  
43
HY-12497 ANA-12
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.
Trk Receptor   NOD-like Receptor (NLR)   AIM2   Caspase  
Depression   Anxiety or Fear-Related Disease   Pain   CNS Infection   Behavioral Addiction  
41
HY-16995 Pirinixic acid
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
PPAR  
Liver Cancer   Digestive System Inflammation   Obesity  
38
HY-B0218 Orlistat
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
Fatty Acid Synthase (FASN)   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Obesity  
37
HY-50935 Troglitazone
Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
PPAR   Autophagy   Apoptosis   Ferroptosis  
Pancreatic Cancer   Depression   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Obesity  
36
HY-17356 Fenofibrate
Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
PPAR   Cytochrome P450   Autophagy  
Digestive System Disease   Breast Cancer   Viral Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism  
36
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-13749 Sitagliptin
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
Dipeptidyl Peptidase   ERK   PKA   GLP Receptor  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
31
HY-N0288 Lycorine
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.
Fatty Acid Synthase (FASN)   Virus Protease   Bacterial   Apoptosis  
Digestive System Disease   Prostate Cancer   Viral Infection   Bacterial Infection   Digestive System Inflammation   Obesity  
25
HY-12216 Resmetirom
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
25
HY-16901 Firsocostat
Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.
Acetyl-CoA Carboxylase  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism   Obesity  
24
HY-W011012 Adenosine 5'-monophosphate disodium
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Adenosine Receptor  
Metabolic or Endocrine Disease  
22
HY-18341 L-Thyroxine
L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
Thyroid Hormone Receptor   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
15
HY-101842 ND-646
ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC50s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.
Acetyl-CoA Carboxylase  
Digestive System Disease   Lung Cancer   Digestive System Inflammation   Obesity  
14
HY-15259 CP-640186
CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation.
Acetyl-CoA Carboxylase  
Digestive System Disease   Digestive System Inflammation   Obesity  
12
HY-N0236 Corylin
Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways.
Antibiotic   STAT  
Infection   Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Depression   Pain   Obesity  
12
HY-13447A PF429242 dihydrochloride
PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.
Fatty Acid Synthase (FASN)   Virus Protease  
Digestive System Disease   Viral Infection   Digestive System Inflammation   Obesity  
12
HY-A0210 Cerulenin
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies.

Source: Cephalosporium caeruleus

Fatty Acid Synthase (FASN)   Fungal   Apoptosis   Antibiotic  
Cancer   Infection   Metabolic or Endocrine Disease  
12
HY-P0059 Teriparatide
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research.
PTHR   Thyroid Hormone Receptor  
Cancer  
12
HY-N7073 Silymarin
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (Mpro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research.
SARS-CoV  
Neurological, Eye or Ear Disease   Liver Cancer   Viral Infection   Digestive System Inflammation   Obesity  
11
HY-101068 TOFA
TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ).
Acetyl-CoA Carboxylase  
Digestive System Disease   Lung Cancer   Ovarian Cancer   Digestive System Inflammation   Obesity  
11
HY-P0055 GLP-1(7-37)
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
GLP Receptor  
Metabolic or Endocrine Disease  
10
HY-112829 Denifanstat
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
9
HY-14823 Sobetirome
Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
7
HY-B1521 Aluminum Hydroxide
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines.
Environmental Pollutants   NOD-like Receptor (NLR)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
7
HY-128851 Coenzyme A
Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
Endogenous Metabolite   Fatty Acid Synthase (FASN)  
Ovarian Cancer   Lipid Metabolism  
6
HY-N0853 Alisol A
Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity.
AMPK   Acetyl-CoA Carboxylase   PPAR   MMP   Interleukin Related  
Breast Cancer   Colorectal Cancer   Glucose Metabolism   Atherosclerosis   Obesity  
5
HY-141513 NH-3
NH-3 is an orally active, reversible thyroid hormone receptor (THR) antagonist with an IC50 of 55 nM. NH-3, a derivative of the selective thyromi-metic GC-1, inhibits binding of thyroid hormones to their receptor and that inhibits cofactor recruitment. NH-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Thyroid Hormone Receptor  
Neurological, Eye or Ear Disease  
5
HY-145953 VY-3-135
VY-3-135 is a potent, orally active, and stable ACSS2 inhibitor with an IC50 value of 44 nM. VY-3-135 is specific to ACSS2 among the AcCoA synthetase family of enzymes. VY-3-135 does not inhibit ACSS1 or ACSS3 enzymatic activity. VY-3-135 can be used for the research of breast cancer.
Acetyl-CoA Carboxylase  
Digestive System Disease   Breast Cancer   Digestive System Inflammation   Obesity  
5
HY-124861 Malic enzyme inhibitor ME1
Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM.
Fatty Acid Synthase (FASN)  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity  
5
HY-12942 PF-05175157
PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively.
Acetyl-CoA Carboxylase  
Digestive System Disease   Digestive System Inflammation   Obesity  
4
HY-B0208 Methimazole
Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Glioblastoma   Graves’ Disease  
4
HY-N6012 (-)-Alkannin
(-)-Alkannin, found in Alkanna tinctoria, is used as a food coloring. (-)-Alkannin shows anticancer activity, arrests cell cycle, and induces apoptosis. (-)-Alkannin improves hepatic inflammation in a Rho-kinase pathway.
Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation  
3
HY-B0346 Propylthiouracil
Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research.
Environmental Pollutants   Thyroid Hormone Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
3
HY-108910 Chymotrypsin
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
Toll-like Receptor (TLR)   NF-κB   MMP  
Breast Cancer   Digestive System Inflammation   Gastric Disease   Metastatic Melanoma   Pharyngitis   Rheumatoid Arthritis  
3
HY-P3506 Retatrutide
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
GCGR   GLP Receptor  
Obesity  
3
HY-P1624A Teduglutide TFA
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Nuclear Hormone Receptor 4A/NR4A   FXR  
Inflammation or Immune System Disease  
2
HY-N8599 Cichoriin
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC50 values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y14R (IC50 = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2.
Amylases   Glycosidase   Lipase   Dipeptidyl Peptidase   p38 MAPK   PPAR   P2Y Receptor   NOD-like Receptor (NLR)   SARS-CoV   Pyroptosis   GLUT   Angiotensin-converting Enzyme (ACE)   NF-κB  
Digestive System Disease   Viral Infection   Digestive System Inflammation   Obesity  
2
HY-N1990 Gypenoside XLIX
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
PPAR   Sirtuin   Keap1-Nrf2   Toll-like Receptor (TLR)   NF-κB   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   Apoptosis   Pyroptosis   Autophagy  
Neurological, Eye or Ear Disease   Atherosclerosis and Inflammation   Acute Lung Injury   Cardiomyopathy   Liver Injury  
2
HY-P10769 MOTS-c (mouse)
MOTS-c (mouse) is a mitochondrial-derived polypeptide that can be used to regulates pancreatic cell function. MOTS-c (mouse) reduces insulin secretion and expression in INS-1E cells, and enhances glucagon secretion and expression in αTC-1 cells. MOTS-c (mouse) decreases the apoptosis in INS-1E and αTC-1. MOTS-c (mouse) counteracts diet-induced obesity and insulin resistance through AMPK activation.
AMPK   Apoptosis  
Pancreatic Cancer   Pain   Digestive System Inflammation   Obesity  
2
HY-N0668 Rubusoside
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
GLUT   NF-κB   Amylases  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
2
HY-N1419 Vaccarin
Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis.
AMPK   Akt   ERK   p38 MAPK   NF-κB   Nuclear Factor of activated T Cells (NFAT)   JNK  
Lung Cancer   Breast Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
2
HY-135981 CMS-121
CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities.
Acetyl-CoA Carboxylase  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation   Obesity  
2
HY-N2118 Bilobetin
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
PPAR   PKA   Akt   p38 MAPK   ERK  
Metabolic or Endocrine Disease   Lung Cancer   Pancreatic Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation  
2
HY-P1624 Teduglutide
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Nuclear Hormone Receptor 4A/NR4A   FXR  
Inflammation or Immune System Disease  
2
HY-N6071R Secoisolariciresinol (Standard)
Artemether (Standard) ((-)-Secoisolariciresinol (Standard)) is the analytical standard of Artemether (HY-N6071). This product is intended for research and analytical applications. Secoisolariciresinol ((-)-Secoisolariciresinol) is a plant lignan and a precursor of enterolignans. Secoisolariciresinol can be converted into enterodiol and enterolactone by intestinal microflora. Secoisolariciresinol may reduce the risk of cancer and cardiovascular diseases.
Reference Standards   Drug Intermediate  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
1
HY-W127601 Lard oil
Lard oil is an orally active biochemical reagent. Lard oil upregulates PERK, eIF2a, CHOP, OPN, TLR2, TLR4, TNF-α, and downregulates GRP78 and IRE1a. Lard oil induces responses such as body fat accumulation, elevated serum insulin levels, increased HOMA-IR, hepatic ectopic lipid deposition, hepatic endoplasmic reticulum stress, and hepatic inflammation. Lard oil can be used in studies related to diet-induced obesity, insulin resistance, and non-alcoholic fatty liver disease.
Biochemical Assay Reagents   PERK   Eukaryotic Initiation Factor (eIF)   Toll-like Receptor (TLR)   TNF Receptor   IRE1  
Insulin Resistance   Obesity  
1
HY-N6071 Secoisolariciresinol
Secoisolariciresinol ((-)-Secoisolariciresinol) is a plant lignan and a precursor of enterolignans. Secoisolariciresinol can be converted into enterodiol and enterolactone by intestinal microflora. Secoisolariciresinol may reduce the risk of cancer and cardiovascular diseases.
Drug Intermediate  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Breast Cancer  
1
HY-N6869 Dehydroabietic acid
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice.
Antibiotic   PPAR   Bacterial   Fungal  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Bacterial Infection   Fungal Infection   Digestive System Inflammation  
1
HY-N0468 Rebaudioside D
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research.
FXR   Acetyl-CoA Carboxylase  
Obesity  
1
HY-W018499 (S)-2-Hydroxybutanoic acid
(S)-2-Hydroxybutanoic acid is the S-enantiomer of 2-Hydroxybutanoic acid. 2-Hydroxybutanoic acid, a coproduct of protein metabolism, is an insulin resistance (IR) biomarker.
Endogenous Metabolite  
1
HY-W105750 6-Hydroxyhexanoic acid
6-Hydroxyhexanoic acid (6-HHA) is a bacterial effector molecule with metabolic and immunomodulatory activities. 6-Hydroxyhexanoic acid activates the JAK1-STAT1 signaling pathway, promotes phenotypic conversion of M2 macrophages to M1 macrophages, and exerts anti-tumor effects by regulating macrophage polarization. 6-Hydroxyhexanoic acid inhibits lipolysis in adipocytes mediated by Gαi family GPCR, and reduces high-fat diet-induced weight gain and obesity. 6-Hydroxyhexanoic acid can be used in studies related to pancreatic ductal adenocarcinoma, obesity, and insulin resistance.
JAK   STAT   Adenylate Cyclase  
Pancreatic Ductal Adenocarcinoma   Insulin Resistance   Obesity  
1
HY-N0732 Jolkinolide B
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma   Fatty Liver Disease  
1
HY-W250122 Glutamic acid sodium salt
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
Biochemical Assay Reagents   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Apoptosis   HSP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-P11274 Zenagamtide
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   GCGR   Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W012722BS 4-Methyl-2-oxopentanoic acid-d7 sodium
4-Methyl-2-oxopentanoic acid-d7 (α-Ketoisocaproic acid-d7) sodium is the deuterium labeled 4-Methyl-2-oxopentanoic acid (HY-W012722).4-Methyl-2-oxopentanoic acid is a metabolite of L-leucine and is involved in energy metabolism. 4-Methyl-2-oxopentanoic acid increases endoplasmic reticulum stress, promotes lipid accumulation in preadipocytes and insulin resistance by impairing mTOR and autophagy signaling pathways.
Endogenous Metabolite   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P3580 Acetyl Gastric Inhibitory Peptide (human)
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-P3866 [Asu1,6]-Oxytocin
[Asu1,6]-Oxytocin is an analog of oxytocin. [Asu1,6]-Oxytocin reverses insulin resistance and glucose intolerance prior to reduction of obesity. [Asu1,6]-Oxytocin has the potential for the research of obesity and diabetes.
Oxytocin Receptor  
Metabolic or Endocrine Disease  
/
HY-P10305 Visepegenatide
PB-119 is a PEGylated Exenatide. PB-119 decreases glycemic levels by improving beta-cell function and insulin resistance. PB-119 can be used for research of type 2 diabetes.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-N3686S1 D-Arabitol-13C-1
D-Arabitol-13C-1 is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-N3686S D-Arabitol-13C
D-Arabitol-13C is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-N3686S2 D-Arabitol-13C-2
D-Arabitol-13C-2 is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-P2501 Amylin (8-37), human
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.
Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-P1824 C-Reactive Protein (CRP) (201-206)
C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
Others  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P1836 C-Reactive Protein (CRP) (77-82)
C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
Others  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P5081 Endotrophin (Mus musculus)
Endotrophin (Mus musculus) is an adipokine, a cleavage fragment derived from Collagen VI, whose levels are elevated in adipose tissue and breast tumors of obese mice. Endotrophin (Mus musculus) activates the TGF-β signaling pathway and reduces the expression of hormone-sensitive lipase. Endotrophin (Mus musculus) induces adipogenesis, lipid accumulation, fibrosis, inflammation, angiogenesis, adipose tissue expansion, epithelial-mesenchymal transition, and insulin resistance; it also induces Cisplatin (HY-17394) resistance in cancer cells. Endotrophin (Mus musculus) can be used in research related to metabolic diseases such as obesity and type 2 diabetes, as well as cancers such as breast cancer.
TGF-β Receptor   Collagen  
Inflammation or Immune System Disease  
/
HY-P5390 GIP, rat
GIP, rat is a bioactive peptide derived from rats. GIP, rat inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes.
Insulin Receptor   Glycosidase  
Type 2 Diabetes   Insulin Resistance  
/
HY-P10897A SjDX5-271v
SjDX5-271v is a negative control of SjDX5-271 (HY-P10897). SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury.
Toll-like Receptor (TLR)   NF-κB  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-W011012R Adenosine 5'-monophosphate disodium (Standard)
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Reference Standards   Adenosine Receptor  
Metabolic or Endocrine Disease  
/
HY-P11358 IRW
IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation.
Angiotensin-converting Enzyme (ACE)   Acetyl-CoA Carboxylase   Mitochondrial Metabolism  
Inflammation or Immune System Disease  
/
HY-13690S2 Mitotane-d8
Mitotane-d8 is the deuterium labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Apoptosis  
Cancer  
/
HY-107737S 1,2-DLPC-d55
1,2-DLPC-d55 (1,2-Dilauroyl-sn-glycero-3-phosphocholine-d55) is the deuterium labeled 1,2-DLPC. 1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells.
Isotope-Labeled Compounds  
/
HY-P11207 NLS-CPP
NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA).
Others  
Inflammation or Immune System Disease  
/
HY-P11208A mNLS-CPP-scramble
mNLS-CPP-scramble is a negative control peptide of mNLS-CPP-WSTF. mNLS-CPP-scramble is promising for research of chronic inflammatory diseases (e.g., MASH, osteoarthritis).
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-N0732R Jolkinolide B (Standard)
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
Reference Standards   IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma  
/
HY-P11208 mNLS-CPP-WSTF
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-13690S3 Mitotane-13C12
Mitotane-13C12 (2,4′-DDD-13C12) is 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Isotope-Labeled Compounds   Apoptosis  
Cancer  
/
HY-P3848 Tyr0-Neurokinin A
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes.
Neurokinin Receptor  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-W011012S1 Adenosine 5'-monophosphate-d2 disodium
Adenosine 5'-monophosphate-d2 disodium is the deuterium labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Isotope-Labeled Compounds  
/
HY-W001288S Indole-4-carboxaldehyde-13C
Indole-4-carboxaldehyde-13C is the 13C-labeled Indole-4-carboxaldehyde (HY-W001288). Indole-4-carboxaldehyde is an ergot alkaloid precursor that regulates glycosylation and inflammation. Indole-4-carboxaldehyde upregulates Glo-1, inhibits MGO-induced NF-κB activation, and suppresses MGO-induced expression of TNF-α and IFN-γ. Indole-4-carboxaldehyde inhibits MGO-induced formation of advanced glycation end products (AGE) and expression of their receptor (RAGE). Indole-4-carboxaldehyde is a core metabolite produced in the pedicels of Summer Black grapes after exogenous gibberellin treatment, and it directly promotes fruit enlargement and fruit set of Summer Black grapes. Indole-4-carboxaldehyde can be used in studies related to hepatic steatosis and plant growth regulation.
Isotope-Labeled Compounds   Glyoxalase (GLO)   NF-κB   TNF Receptor   Drug Intermediate  
Fatty Liver Disease  
/
HY-121246S Fluorofenidone-d3
Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).
Isotope-Labeled Compounds   ACSL Family   NF-κB   ERK   TGF-beta/Smad  
Inflammation or Immune System Disease   Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P1624S Teduglutide-Ala(13C3,15N) sodium
Teduglutide-Ala(13C3,15N) (ALX-0600-Ala(13C3,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-N0668R Rubusoside (Standard)
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
GLUT   Reference Standards   NF-κB   Amylases  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-107737R 1,2-DLPC (Standard)
1,2-DLPC (Standard) is the analytical standard of 1,2-DLPC (HY-107737). This product is intended for research and analytical applications. 1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breaKdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells.
Reference Standards   Liposome   Apoptosis   TNF Receptor   PPAR  
/
HY-B1907R Rifamycin sodium (Standard)
Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.
Reference Standards   Bacterial   Antibiotic  
Infection  
/
HY-100713S Temocapril-d5
Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990252 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.

Species: Mouse

Notch   Interleukin Related   NF-κB   VEGFR   FGFR   NO Synthase  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N6012R (-)-Alkannin (Standard)
(-)-Alkannin, found in Alkanna tinctoria, is used as a food coloring. (-)-Alkannin shows anticancer activity, arrests cell cycle, and induces apoptosis. (-)-Alkannin improves hepatic inflammation in a Rho-kinase pathway.
Reference Standards   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-N0688R Linderane (Standard)
Linderane (Standard) is the analytical standard of Linderane (HY-N0688). This product is intended for research and analytical applications. Linderane is an orally active natural sesquiterpene lactone with blood-brain barrier permeability. Linderane indirectly activates PDE3 by activating ERK/STAT3, thereby inhibiting the cAMP/PKA/CREB signaling pathway and hepatic gluconeogenesis. Linderane protects pancreatic β cells against oxidative damage by inhibiting the activation of the p38 MAPK pathway and activating the Nrf2 pathway. Linderane inhibits cell apoptosis and ameliorates intestinal mucosal inflammation by suppressing the IL-6/JAK/STAT3 signaling pathway. Linderane reduces pain sensitivity and alleviates anxiety-like behaviors by activating cannabinoid receptor 2 (CB2R). Linderane can be used in studies related to type 2 diabetes, ulcerative colitis, and chronic inflammatory pain with anxiety.
Reference Standards   ERK   STAT   Phosphodiesterase (PDE)   PKA   p38 MAPK   Keap1-Nrf2   JAK   Interleukin Related   Apoptosis   Cannabinoid Receptor  
Pain   Type 2 Diabetes   Ulcerative Colitis  
/
HY-P10897 SjDX5-271
SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury.
Toll-like Receptor (TLR)   NF-κB  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P1624S1 Teduglutide-Leu(13C6,15N) sodium
Teduglutide-Leu(13C6,15N) (ALX-0600-Leu(13C6,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-N9610 Coenzyme Q6
Coenzyme Q6 (Ubiquinone 30) is a redox-active benzoquinone lipid and mitochondrial electron carrier. Coenzyme Q6 can be used in research on MASLD, mitochondrial diseases, pneumococcal diseases, and steroid-resistant nephrotic syndrome with FSGS.

Source: saccharomyces

Endogenous Metabolite  
Renal Disease   Streptococcus Pneumoniae Infection   Fatty Liver Disease  
/
HY-W011012S Adenosine 5'-monophosphate-13C disodium
Adenosine 5'-monophosphate-13C (disodium) is a 13C-labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Isotope-Labeled Compounds  
/
HY-P11208C mNLS-CPP-WSTF TFA
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-N9410S Lysophosphatidylcholine 18:2-d9
Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-13690S1 Mitotane-13C6
Mitotane-13C6 is the 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions.
Apoptosis  
Cancer  
/
HY-Y0399S L-Norvaline-d5
L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Isotope-Labeled Compounds   Amyloid-β   TNF Receptor   Arginase  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P11208B mNLS-CPP-scramble TFA
mNLS-CPP-scramble (TFA) is the trifluoroacetate salt of mNLS-CPP-scramble (HY-P11208A). mNLS-CPP-scramble is a negative control peptide of mNLS-CPP-WSTF. mNLS-CPP-scramble is promising for research of chronic inflammatory diseases (e.g., MASH, osteoarthritis).
GABA Receptor  
Inflammation or Immune System Disease  
/
HY-N13250 Hawthorn Extract
Hawthorn Extract is an orally active hawthorn extract. Hawthorn Extract decreases Bax expression and increases Bcl-2 expression in the aorta. Hawthorn Extract regulates the AMPK signaling pathway, induces apoptosis, enhances the hepatic antioxidant system, and ameliorates symptoms of liver injury, inflammation and cancer. Hawthorn Extract reduces plasma levels of pro-inflammatory factors, increases plasma levels of anti-inflammatory adiponectin, and alleviates atherosclerotic plaque lesions in the aorta. Hawthorn Extract improves symptoms associated with chronic heart failure. Hawthorn Extract inhibits FMLP-induced superoxide anion production, Elastase release, ILB4 generation and calcium signaling in neutrophils, and also reduces LPS-induced cytokine production in neutrophils. Hawthorn Extract induces autophagy and inhibits the proliferation of intestinal stem cells. Hawthorn Extract can be used in research related to atherosclerosis, hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, chronic heart failure and hypotension.
Apoptosis   AMPK   Elastase   Bcl-2 Family   Interleukin Related   Caspase   PI3K   Akt   SOD  
Blood or Cardio-cerebrovascular Disease  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P3580A Acetyl Gastric Inhibitory Peptide (human) TFA
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-P991290 IRAB-B
IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes.

Species: Human

Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W001288 Indole-4-carboxaldehyde
Indole-4-carboxaldehyde is an ergot alkaloid precursor that regulates glycosylation and inflammation. Indole-4-carboxaldehyde upregulates Glo-1, inhibits MGO-induced NF-κB activation, and suppresses MGO-induced expression of TNF-α and IFN-γ. Indole-4-carboxaldehyde inhibits MGO-induced formation of advanced glycation end products (AGE) and expression of their receptor (RAGE). Indole-4-carboxaldehyde is a core metabolite produced in the pedicels of Summer Black grapes after exogenous gibberellin treatment, and it directly promotes fruit enlargement and fruit set of Summer Black grapes. Indole-4-carboxaldehyde can be used in studies related to hepatic steatosis and plant growth regulation.
Glyoxalase (GLO)   NF-κB   TNF Receptor   Drug Intermediate  
Fatty Liver Disease  
/
HY-N0688 Linderane
Linderane is an orally active natural sesquiterpene lactone with blood-brain barrier permeability. Linderane indirectly activates PDE3 by activating ERK/STAT3, thereby inhibiting the cAMP/PKA/CREB signaling pathway and hepatic gluconeogenesis. Linderane protects pancreatic β cells against oxidative damage by inhibiting the activation of the p38 MAPK pathway and activating the Nrf2 pathway. Linderane inhibits cell apoptosis and ameliorates intestinal mucosal inflammation by suppressing the IL-6/JAK/STAT3 signaling pathway. Linderane reduces pain sensitivity and alleviates anxiety-like behaviors by activating cannabinoid receptor 2 (CB2R). Linderane can be used in studies related to type 2 diabetes, ulcerative colitis, and chronic inflammatory pain with anxiety.
ERK   STAT   Phosphodiesterase (PDE)   PKA   p38 MAPK   Keap1-Nrf2   JAK   Interleukin Related   Apoptosis   Cannabinoid Receptor  
Pain   Type 2 Diabetes   Ulcerative Colitis  
/
HY-N5020 Carabrone
Carabrone is a sesquiterpene found in the fruits of Carpesium abrotanoides and acts as a STAT3 inhibitor (Kd = 25.23 nM) with antibacterial, antitumor, and orally active properties. Carabrone covalently binds to UBE2D3 via Cys85 (Kd = 3.85 μM) and inhibits IκBα phosphorylation and NF-κB signaling. Carabrone induces ROS accumulation, loss of mitochondrial membrane potential, DNA fragmentation, and metacaspase-1-mediated apoptosis in fungi. Carabrone ameliorates autoimmune encephalomyelitis and MASH in vivo, reduces pro-inflammatory cytokines without immunotoxicity. Carabrone is used in research related to autoimmune encephalomyelitis, steatohepatitis, and fungal infections.
STAT   Fungal   NF-κB   Reactive Oxygen Species (ROS)   Apoptosis  
Cancer   Fungal Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-126359 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease.
Endogenous Metabolite  
Metabolic or Endocrine Disease   Heart Disease  
/
HY-156193 PF-07208254
PF-07208254 is a selective, orally active allosteric inhibitor of branched-chain ketoacid dehydrogenase kinase (BDK) (IC50=110 nM, Ki=54 nM, KD=84 nM). PF-07208254 inhibits BDK-mediated BCKDH phosphorylation and enhances the catabolism of branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs) by binding to the allosteric pocket of BDK, reducing BDK binding to BCKDH-E2 and promoting BDK degradation. PF-07208254 inhibits BDK activity in human skeletal muscle cells (IC50=540 nM) and has activity to improve cardiac function and metabolism. PF-07208254 can be used in the study of cardiometabolic diseases (e.g., heart failure, type 2 diabetes).
PDHK  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-114118CP Semaglutide (crude)
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-147004 A-908292
A-908292 is a potent and selective acetyl-CoA carboxylase 2 (ACC2) inhibitor, with an IC50 of 23 nM for human ACC2. A-908292 can be used for the research of fatty acid metabolism. A-908292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Acetyl-CoA Carboxylase  
Digestive System Disease   Digestive System Inflammation   Obesity  
/
HY-141578 C18:1-Ceramide
C18:1-Ceramide is a ceramide subspecies belonging to bioactive lipids. C18:1-Ceramide exhibits activities of inducing skeletal muscle insulin resistance and affecting metabolism. C18:1-Ceramide can be used in the research of obesity, type 2 diabetes (T2D), insulin resistance and other related metabolic diseases.
Endogenous Metabolite  
Type 2 Diabetes   Insulin Resistance   Obesity  
/
HY-P5390A GIP, rat TFA
GIP, rat TFA is a bioactive peptide derived from rats. GIP, rat TFA inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat TFA can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes.
Insulin Receptor   Glycosidase  
Type 2 Diabetes   Insulin Resistance  
/
HY-B1907 Rifamycin sodium
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.

Source: fermentation of A. mediterranei or its mutants

Antibiotic   Bacterial   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Mycobacterium Tuberculosis Infection  
/
HY-125848 Ginsenoside F2
Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
Apoptosis   AMPK   PPAR   p38 MAPK   PI3K   Akt   GSK-3   Reactive Oxygen Species (ROS)   SOD   Caspase  
Liver Cancer   Glioblastoma   Atopic Dermatitis   Obesity  
/
HY-N3021 D-chiro-Inositol
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.
Endogenous Metabolite   NF-κB   TNF Receptor   FOXO   Microtubule/Tubulin  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-129109 NBD-Pen
NBD-Pen is the first fluorescence probe for lipid radicals with high selectivity and sensitivity (λex: 470 nm, λem: 530 nm). NBD-Pen specifically detects lipid derived radicals over other reactive species present in biological systems, including H2O2, ClO-, O2-?, and ?OH. NBD-Pen directly detects lipid radicals in living cells by turn-on fluorescence. NBD-Pen decreases inflammation, apoptosis, and oxidative stress markers. NBD-Pen can be studied in various disease models such as hepatic carcinoma.
Fluorescent Dye  
Cancer   Inflammation or Immune System Disease  
/
HY-Y0399 L-Norvaline
L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Amyloid-β   TNF Receptor   Arginase  
Metabolic or Endocrine Disease   Breast Cancer   Alzheimer's Disease   Lung Fibrosis  
/
HY-N6804 Diammonium Glycyrrhizinate
Diammonium glycyrrhizinate is a substance that can be extracted and purified from a traditional Chinese medicinal herb. Diammonium glycyrrhizinate has anti-inflammatory effect, resistance to biologic oxidation, membranous protection and a weak steroidal action. Diammonium glycyrrhizinate exerts protective effect by downregulating inflammation cytokines, suppressing the NF-κB pathway, and restoring superoxide dismutase. Diammonium glycyrrhizinate can be used as a hepatic protector and can therefore be studied in research for most liver diseases.
NF-κB   Reactive Oxygen Species (ROS)  
Pancreatic Cancer   Pain   Digestive System Inflammation  
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
Estrogen Receptor/ERR   Histone Methyltransferase   Thyroid Hormone Receptor   PI3K   Akt   mTOR   Androgen Receptor   Drug Derivative  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease  
/
HY-P11274A Zenagamtide sodium
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   Insulin Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-P4153 Enlicitide chloride
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.
PCSK9  
Blood or Cardio-cerebrovascular Disease  
/
HY-N9410 Lysophosphatidylcholine 18:2
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P4146 Survodutide
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes   Obesity  
/
HY-P3375 Mazdutide
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D).
GCGR   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-P81381 MASH1/Achaete-scute homolog 1 Antibody (YA1126)
MASH1/Achaete-scute homolog 1 Antibody (YA1126) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81381A MASH1/Achaete-scute homolog 1 Antibody (YA1126)(PBS only)
MASH1/Achaete-scute homolog 1 Antibody (YA1126) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P88034 MASH1/Achaete-scute homolog 1 Antibody (YA7719)
MASH1/Achaete-scute homolog 1 Antibody (YA7719) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MASH1/Achaete-scute homolog 1.

Host: Rabbit

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/

Keywords

MASLD | metabolic dysfunction-associated steatotic liver disease | MASH | cardiovascular risk | insulin resistance | lipotoxicity | hepatic inflammation | cardiometabolic disease